gamma-Glutamylcysteine

Summary

Gamma‑glutamylcysteine (γ‑GC) is a dipeptide composed of glutamate linked to cysteine. It is the immediate biosynthetic precursor of the tripeptide glutathione (GSH) and occurs naturally in many organisms, including humans, archaea and some bacteria. In research settings γ‑GC is investigated for its ability to raise intracellular GSH levels and thereby support antioxidant defenses, redox signaling, and cellular health.

Mechanism of Action

γ‑GC is produced in the cytosol by the enzyme glutamate‑cysteine ligase (also called γ‑glutamylcysteine synthetase), the rate‑limiting step of GSH synthesis. It is then ligated with glycine by glutathione synthetase to form GSH. By supplying the rate‑limiting intermediate, γ‑GC can bypass cysteine‑dependent regulation, enhancing GSH biosynthesis, which in turn fuels glutathione‑peroxidase, glutathione‑transferase and reductase activities that detoxify peroxides and maintain redox homeostasis.

What the Research Shows

Reviews of GSH metabolism describe γ‑GC as the key intermediate whose availability controls GSH production, especially when cysteine becomes limiting (Wu et al., 2004). Age‑related declines in GSH are linked to reduced γ‑GC synthesis, and higher GSH levels correlate with better healthspan (Lapenna, 2023). In archaea, γ‑GC is the major low‑molecular‑weight thiol, indicating a conserved redox role across domains (Fahey, 2001). Studies on the enzyme cystathionine γ‑lyase show that increased H2S production up‑regulates γ‑glutamylcysteine synthetase, boosting GSH (Jurkowska et al., 2014). In the ocular lens, oxidative stress leads to formation of protein‑γ‑glutamylcysteine mixed disulfides, implicating γ‑GC in early cataractogenic changes (Lou, 2003). No clinical trials of isolated γ‑GC supplementation were identified.

Reported Benefits

By providing the rate‑limiting substrate for GSH synthesis, γ‑GC has the theoretical potential to raise intracellular GSH, supporting antioxidant defenses, detoxification pathways, and redox‑regulated signaling. Pre‑clinical observations suggest possible benefits for age‑related oxidative stress, maintenance of lens transparency, and modulation of H2S‑mediated vascular effects, although direct human evidence is lacking.

Limitations of the Evidence

The literature does not contain human intervention studies of γ‑GC; benefits are inferred from its role in GSH biosynthesis and from related animal or cellular data. Effects on clinical outcomes such as aging, cataract formation, or cardiovascular health remain speculative. Moreover, the optimal dose, formulation, and long‑term safety have not been established, representing significant gaps before therapeutic conclusions can be drawn.

Safety Considerations

No adverse events or toxicity data for isolated γ‑GC are reported in the cited abstracts. Because it is classified as a research‑only compound, safety in humans has not been formally evaluated. Potential concerns include unknown metabolic interactions, especially at high doses, and the possibility of altering cysteine homeostasis. Caution is advised until systematic toxicology studies are performed.

How It Is Administered

γ‑GC can be delivered intravenously, orally, or topically in experimental settings. Formulations described in the literature are limited to laboratory preparations; no commercial pharmaceutical products are noted. Route selection in studies depends on the target tissue (e.g., systemic versus ocular application).

Routes of Administration

Goals & Uses

• increase glutathioneAntioxidant SupportModerate
• Oxidative stress reductionAntioxidantModerate
• Glutathione replenishmentAntioxidant / CytoprotectionModerate
• NeuroprotectionNeurologyLow
• HepatoprotectionCytoprotectionLow
• Skin anti-aging / brighteningCosmetic / DermatologyLow

Contraindications

• Known hypersensitivity to γ-GC or structurally related compoundsAllergyHigh
• Cystinuria or cystine stone diseaseMetabolic DisorderModerate
• cystinuriaMetabolic DisorderModerate

Adverse Effects

• Injection site irritationLocal ReactionUncommon
• Gastrointestinal upsetGastrointestinalCommon
• Theoretical pro-oxidant effects at supraphysiologic dosesOxidativeUnknown
• Sulfur-related gastrointestinal discomfortGastrointestinalUncommon

Drug Interactions

• Cisplatin / alkylating chemotherapeuticsModerate
• Buthionine sulfoximine (BSO)Moderate
• N‑acetylcysteineLow

Population Constraints

• PregnancyReproductive SafetyRelative
• Renal impairmentOrgan ImpairmentRelative
• Pediatric populationAgeRelative
• Pregnant womenReproductiveRelative

Regulatory Status

• European UnionUnapprovedmarketed as food supplement under novel food regulations
• United StatesUnapprovedavailable as dietary supplement, not an FDA‑approved drug
• United KingdomUnapprovedNot approved by MHRA as a medicinal product.

Not approved as a drug by FDA, EMA, or MHRA. Available as a research chemical and appears in some dietary supplement formulations. No IND or NDA on record as a standalone therapeutic.

Evidence & Sources

• Glutathione and glutathione-dependent enzymes: From biochemistry to gerontology and successful aging
  Journal ArticleModerateLapenna D2023-01-01T00:00:00.000000Z
• Redox and Thiols in Archaea
  Journal ArticleModerateRawat M, Maupin-Furlow JA2020-01-01T00:00:00.000000Z
• Glutathione metabolism and its implications for health
  Journal ArticleModerateWu G, et al.2004-01-01T00:00:00.000000Z
• [Cystathionine γ-lyase]
  Journal ArticleModerateJurkowska H, et al.2014-01-01T00:00:00.000000Z
• Novel thiols of prokaryotes
  Journal ArticleModerateFahey RC2001-01-01T00:00:00.000000Z
• Redox regulation in the lens
  Journal ArticleModerateLou MF2003-01-01T00:00:00.000000Z

Frequently Asked Questions